Lorlatinib

Lorbrena

Kinase Inhibitor

NADAC/unit N/A

No Shortage Tier 1: 35.9% PA Req: 198.8%

Lorlatinib targets specific kinase enzymes involved in cancer cell growth and proliferation.

Covered Lives

Generic Manufacturers

PFIZER INC

Explore in the Ecosystem

rxsaver.aiCompare prices for Lorlatinib drfinder.aiFind doctors who prescribe Lorlatinib rxpbm.aiPBM spread analysis for Lorlatinib clinicalrx.aiClinical profile: Lorlatinib

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.